Table 1.
Effect of Rifampicin on S-ketamine and Norketamine Concentrations: CMAX, TMAX and Area-Under-the-Curve (AUC) Values.
| Placebo | Rifampicin | P-value | |
|---|---|---|---|
|
|
|||
| [S-ketamine]20 | |||
| CMAX (ng/ml) | 150.4 ± 3.9 | 132.6 ± 7.1 | < 0.001 |
| TMAX (min) | 114 ± 3 | 113 ± 4 | 0.72 |
| AUC0→300 (ng/ml) | 71.5 ± 5.4 | 60.8 ± 5.1 | < 0.001 |
| [S-norketamine]20 | |||
| CMAX (ng/ml) | 113.8 ± 5.9 | 64.5 ± 8.7 | 0.001 |
| TMAX (min) | 129 ± 2 | 125 ± 1 | 0.06 |
| AUC0→300 (ng/ml) | 73.3 ± 8.4 | 35.5 ± 11.7 | < 0.001 |
| AUCM/AUCP | 1.03 ± 0.19 | 0.58 ± 0.19 | < 0.001 |
| [S-ketamine]40 | |||
| CMAX (ng/ml) | 304.7 ± 17.5 | 285.6 ± 14 | 0.27 |
| TMAX (min) | 110 ± 5 | 113 ± 3 | 0.51 |
| AUC0→300 (ng/ml) | 142 ± 15.8 | 132.0 ± 17.4 | 0.02 |
| [S-norketamine]40 | |||
| CMAX (ng/ml) | 198.3 ± 8.1 | 83.6 ± 6.2 | < 0.001 |
| TMAX (min) | 132 ± 2 | 128 ± 2 | 0.17 |
| AUC0→300 (ng/ml) | 124.8 ± 18.5 | 47.9 ± 11.6 | < 0.001 |
| AUCM/AUCP | 0.90 ± 0.12 | 0.36 ± 0.10 | < 0.001 |
AUC0→300 = the area-under-the-curve determined over the 300 min study period divided by 300 min; CMAX is the peak concentration; TMAX is the time of occurrence of CMAX.
20 and 40 denote data obtained during and after the 2-h infusion of 20 mg/h and 40 mg/h S-ketamine infusion (both per 70 kg), respectively.
AUCP = the parent AUC0→300 (S-ketamine); AUCM = the metabolite AUC0→300 (S-norketamine).
Values are mean ± SD.